Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (34)

I-007Mahmoud Ali

mastering upset plots: a comprehensive tutorial for effective data visualization in pharmacometrics and drug development

Wednesday 10:20-11:50

I-008Nikolaos Alimpertis

Leveraging the Finite Absorption Time (F.A.T.) Concept for Advancing PBPK Modeling and Pharmacometric structural models: Moving MIDD to Model Informed Drug Development and Assessment (MIDDA)

Wednesday 10:20-11:50

I-012Innocent Asiimwe

The Applied Pharmacometrics Training Program – Year 3 Sustainability

Wednesday 10:20-11:50

I-014Sally Babiker

Dose rationale for bedaquiline in paediatric patients with multi drug-resistant tuberculosis

Wednesday 10:20-11:50

I-017Pavel Balazki

User-friendly and Quality-Controlled PBPK/QSP M&S Framework in R for Regulatory Submissions using Open Systems Pharmacology Software

Wednesday 10:20-11:50

I-079Giuseppe De Nicolao

A mixed effect multi-funnel model for country surveillance of antibiotic resistance: evidence from the WHO GLASS dashboard

Wednesday 10:20-11:50

I-088Giovanni Di Veroli

Bridging the gap between secondary pharmacology and hemodynamics findings via Quantitative Systems modelling

Wednesday 10:20-11:50

I-101Alan Faraj

Model-based approaches to prospectively power pediatric pharmacokinetic trials with limited sample size

Wednesday 10:20-11:50

I-110Sophie Fischer-Holzhausen

Development of a gestational Physiologically Based Kinetic model to predict rat dam and fetus exposure in PK-Sim/MoBi

Wednesday 10:20-11:50

I-112Thomas Frank

Automating pharmacometrics reporting using R Markdown

Wednesday 10:20-11:50

II-033Niels Hendrickx

Evaluation of treatment effects in genetic ataxias using SARA score modelling: comparison of multiple trial designs by a large trial simulation framework

Wednesday 15:20-16:50

II-037Sara Carolina Henriques

Unveiling the Potential of Cmax ƒ2 Factor Applied to Pilot Bioavailability/Bioequivalence Studies

Wednesday 15:20-16:50

II-043Andrew Hooker

Generating uncertainty estimates in empirical forest plots

Wednesday 15:20-16:50

II-045Ziheng Hu

Choice of Exposure Metric in Exposure-Response Modeling

Wednesday 15:20-16:50

II-051Ibrahim Ince

Qualification of the Open Systems Pharmacology PBPK modeling Platform for simulation of transporter Drug-Drug-Interactions

Wednesday 15:20-16:50

II-068Daniel Kaschek

Using the M3 Method in Exploratory Plots and in NCA

Wednesday 15:20-16:50

II-069Csaba Katai

An asymptotic description of a basic FcRn-regulated clearance mechanism and its implications for PBPK modelling of large antibodies

Wednesday 15:20-16:50

II-097Valentin Legras

Sunburst Plots for Analyzing the Impact of Drugs on CRS

Wednesday 15:20-16:50

III-011John Maringwa

Assessing Approaches for Handling Missing Precision Measures Issue in Model-Based Meta Analysis (MBMA)

Thursday 09:50-11:20

III-029Zeyar Mohammed Ali

Evaluation of extrapolation potential of IMPRES-M, a non-parametric Impulse-Response Modeling framework when applied to pharmacokinetic profiles of different dosing frequencies

Thursday 09:50-11:20

III-065Mariana Pereira

Etravirine’s Pharmacokinetics Explored: PBPK Modeling and DDI Analysis with Efavirenz for Cancer Treatment

Thursday 09:50-11:20

III-074Cesar Pichardo

The International Society of Pharmacometrics’ Special Interest Group on Quantitative Systems Pharmacology (ISoP QSP SIG): Recent Developments and Future Vision

Thursday 09:50-11:20

III-083Anne Ravix

Numerical validation of Tucuxi, a promising new Bayesian adaptation tool

Thursday 09:50-11:20

III-093Matthew Riggs

bbr.bayes: An Open-Source Tool to Facilitate an Efficient, Reproducible Bayesian Workflow Using NONMEM

Thursday 09:50-11:20

III-108Andrew Santulli

nonmem2mrgsolve: An R package for Automated NONMEM to mrgsolve Translation

Thursday 09:50-11:20

IV-010Erik Sjögren

Absorption, Bioavailability, and Immunogenicity after Subcutaneous Administration: Evaluation of a Subcutaneous Platform within the Open Systems Pharmacology framework

Thursday 15:00-16:30

IV-034Florencia Tettamanti

Predicting Progression Free Survival from Measurable Residual Disease (MRD) in Chronic Lymphocytic Leukemia (CLL)

Thursday 15:00-16:30

IV-065Peter Velickovic

Translational pharmacology and dose rationale for imatinib and doramapimod as a host-directed therapy for the treatment of pulmonary tuberculosis

Thursday 15:00-16:30

IV-069Laura Villain

Considerations for the application of PBPK to optimize drug therapies in special populations: The Open Systems Pharmacology solutions

Thursday 15:00-16:30

IV-087Mélanie Wilbaux

How to handle population pharmacokinetics modeling in the context of a regulatory submission for a compound already well-characterized in other settings? A case-study with nivolumab in urothelial cancer.

Thursday 15:00-16:30

IV-089Insa Winzenborg

Uncovering Bias in Exposure-Response Relationships: Investigating the Impact of Exposure Calculation for Irregular Dosing Regimens

Thursday 15:00-16:30

IV-090Daniel Wojtyniak

Influential factors on the type I error rate in pharmacometrics models using individual model averaging or standard approach

Thursday 15:00-16:30

IV-099Koichiro Yoneyama

Impact of Imbalanced Baseline Responses among Dose Levels in the Exposure-Response Analysis by Nonlinear Mixed-Effect Modeling

Thursday 15:00-16:30

IV-114Jochen Zisowsky

Target-mediated drug disposition of monoclonal antibody binding to plasma soluble target: some insights from PBPK/PD and popPK/PD approaches

Thursday 15:00-16:30